NO952601L - Oligonukleotider for inhibering av ekspresjon av isoprenylprotein-transferaser - Google Patents

Oligonukleotider for inhibering av ekspresjon av isoprenylprotein-transferaser

Info

Publication number
NO952601L
NO952601L NO952601A NO952601A NO952601L NO 952601 L NO952601 L NO 952601L NO 952601 A NO952601 A NO 952601A NO 952601 A NO952601 A NO 952601A NO 952601 L NO952601 L NO 952601L
Authority
NO
Norway
Prior art keywords
oligonucleotides
expression
inhibition
protein transferases
isoprenyl protein
Prior art date
Application number
NO952601A
Other languages
English (en)
Other versions
NO952601D0 (no
Inventor
Soudhir Colote
Eduardo Pirotzky
Original Assignee
Scras
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scras filed Critical Scras
Publication of NO952601D0 publication Critical patent/NO952601D0/no
Publication of NO952601L publication Critical patent/NO952601L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y205/00—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5)
    • C12Y205/01—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5) transferring alkyl or aryl groups, other than methyl groups (2.5.1)
    • C12Y205/01029—Geranylgeranyl diphosphate synthase (2.5.1.29)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)

Abstract

Oppfinnelsen vedrører oligonukleotider og deres derivater for inhibering av ekspresjonen av isoprenylprotein-: transferaser, terapeutiske blandinger som inneholder slike forbindelser og anvendelsen av slike blandinger av oligonukleotider til behandling eller terapi av sykdommer hos dyr eller mennesker, indusert gjennom en abnorm og/eller ukontrollert cellulær proliferasjon.i
NO952601A 1994-06-29 1995-06-28 Oligonukleotider for inhibering av ekspresjon av isoprenylprotein-transferaser NO952601L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9413035A GB9413035D0 (en) 1994-06-29 1994-06-29 Antisense oligonucleeotides

Publications (2)

Publication Number Publication Date
NO952601D0 NO952601D0 (no) 1995-06-28
NO952601L true NO952601L (no) 1996-01-02

Family

ID=10757497

Family Applications (1)

Application Number Title Priority Date Filing Date
NO952601A NO952601L (no) 1994-06-29 1995-06-28 Oligonukleotider for inhibering av ekspresjon av isoprenylprotein-transferaser

Country Status (25)

Country Link
US (1) US5856461A (no)
EP (1) EP0692535A1 (no)
JP (1) JPH0851985A (no)
KR (1) KR960000914A (no)
CN (1) CN1124142A (no)
AU (1) AU689887B2 (no)
BR (1) BR9503015A (no)
CA (1) CA2152233A1 (no)
CZ (1) CZ291496B6 (no)
DZ (1) DZ1903A1 (no)
FI (1) FI953170A (no)
FR (2) FR2721930B1 (no)
GB (2) GB9413035D0 (no)
HU (1) HU219823B (no)
IE (1) IE950477A1 (no)
MA (1) MA23595A1 (no)
NO (1) NO952601L (no)
NZ (1) NZ272398A (no)
OA (1) OA10221A (no)
PL (1) PL309384A1 (no)
RU (1) RU2112766C1 (no)
SE (1) SE9502259L (no)
SK (1) SK83895A3 (no)
TN (1) TNSN95068A1 (no)
ZA (1) ZA955288B (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11509204A (ja) * 1995-07-13 1999-08-17 ユニバーシテイ・オブ・シンシナテイ 神経線維腫症の治療に有用な化合物
CN1301731A (zh) * 1999-12-24 2001-07-04 上海博德基因开发有限公司 一种新的多肽——多异戊二烯基合成酶蛋白9和编码这种多肽的多核苷酸
WO2002046414A2 (en) * 2000-12-07 2002-06-13 Bristol-Myers Squibb Company Human g-protein coupled receptor expressed highly in kidney
US20030212017A1 (en) * 2002-05-10 2003-11-13 Isis Pharmaceuticals Inc. Antisense modulation of farnesyl transferase beta subunit expression
US7507808B2 (en) * 2002-12-12 2009-03-24 Isis Pharmaceuticals, Inc. Modulation of endothelial lipase expression
DK1667522T3 (en) * 2003-09-09 2018-03-05 Geron Corp MODIFIED OLIGONUCLEOTIDES FOR TELOMERASE INHIBITION
WO2008094640A2 (en) * 2007-01-30 2008-08-07 Geron Corporation Compounds having anti-adhesive effects on cancer cells
JOP20200257A1 (ar) 2014-05-01 2017-06-16 Geron Corp تركيبات أوليجو نوكليوتيد وطرق لتحضيرها

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4571421A (en) * 1979-11-05 1986-02-18 Genentech, Inc. Mammalian gene for microbial expression
US5004803A (en) * 1988-11-14 1991-04-02 Genetics Institute, Inc. Production of procoagulant proteins
US5420245A (en) * 1990-04-18 1995-05-30 Board Of Regents, The University Of Texas Tetrapeptide-based inhibitors of farnesyl transferase
US5185248A (en) * 1990-05-08 1993-02-09 E. R. Squibb & Sons, Inc. Farnesyl-protein transferase assay for identifying compounds that block neoplastic transformation
EP0575491B1 (en) * 1991-03-07 2003-08-13 Virogenetics Corporation Genetically engineered vaccine strain
NZ244820A (en) * 1991-10-25 1994-01-26 Isis Pharmaceuticals Inc Oligonucleotide inhibitor of epstein-barr virus.
US5348853A (en) * 1991-12-16 1994-09-20 Biotronics Corporation Method for reducing non-specific priming in DNA amplification
US5585479A (en) * 1992-07-24 1996-12-17 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human ELAM-I RNA

Also Published As

Publication number Publication date
GB2290791B (en) 1998-08-05
DZ1903A1 (fr) 2002-02-17
EP0692535A1 (fr) 1996-01-17
HU9501913D0 (en) 1995-08-28
FI953170A0 (fi) 1995-06-27
TNSN95068A1 (fr) 1996-02-06
GB9413035D0 (en) 1994-08-17
RU95110774A (ru) 1997-04-20
US5856461A (en) 1999-01-05
SK83895A3 (en) 1996-05-08
HUT72133A (en) 1996-03-28
FR2721827A1 (fr) 1996-01-05
BR9503015A (pt) 1996-06-04
OA10221A (fr) 1997-09-19
PL309384A1 (en) 1996-01-08
SE9502259L (sv) 1995-12-30
FR2721930B1 (fr) 1997-01-03
ZA955288B (en) 1996-01-31
CN1124142A (zh) 1996-06-12
GB9513246D0 (en) 1995-09-06
RU2112766C1 (ru) 1998-06-10
GB2290791A (en) 1996-01-10
AU2329995A (en) 1996-01-11
IE950477A1 (en) 1996-01-10
FI953170A (fi) 1995-12-30
CZ168895A3 (en) 1996-05-15
KR960000914A (ko) 1996-01-25
CA2152233A1 (en) 1995-12-30
AU689887B2 (en) 1998-04-09
NO952601D0 (no) 1995-06-28
CZ291496B6 (cs) 2003-03-12
SE9502259D0 (sv) 1995-06-21
NZ272398A (en) 1996-04-26
JPH0851985A (ja) 1996-02-27
FR2721930A1 (fr) 1996-01-05
HU219823B (hu) 2001-08-28
MA23595A1 (fr) 1995-12-31

Similar Documents

Publication Publication Date Title
ATE200677T1 (de) Substituierte tetra- und pentapeptid hemmstoffe der farnesyl protein transferase
ATE397621T1 (de) Hemmer der interaktion zwischen p53 und mdm2
NO20055863L (no) W-karboksyarylsubstituerte difenylureaforbindelser som raf-kinaseinhibitorer
NO992400L (no) Nye substituerte pyrazolderivater
DE60225556D1 (de) Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes
NO965604L (no) Histidin- og homohistidin-derivater som inhibitorer for protein-farnesyltransferase
NO991732L (no) Nye heterocyklylmetylsubstituerte pyrazolderivater
DE50310516D1 (de) Fredericamycin-derivate
NO20051966L (no) Nye pyrimidinamidderivater og anvendelse derav
BRPI0518315B8 (pt) compostos de tiazol que modulam a atividade da proteína hsp90, métodos de inibição, tratamento e indução associados e composição farmacêutica
CY1105125T1 (el) Χρηση αναστολεων ακετυλοχολινεστepασης για την παρασκευη φαρμακευτικων συνθεσεων για τη θepαπευτικη αντιμετωπιση συνδρομων λειτουργικων και/ή οργανικων πονων
SE9800836D0 (sv) New Compounds
NO20051404L (no) Pyridylsubstituerte heterocykluser som er nyttige for behandling eller forebyggelse av HCV infeksjon
DK0662948T3 (da) 2-amino-4-phenyl-4-oxosmørsyrederivater med kynureninase- og/eller kynurenin-3-hydroxylaseinhiberende virkning
GR910100067A (el) Αναστολείς αρωματάσης.
ATE302002T1 (de) Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit
NO952601L (no) Oligonukleotider for inhibering av ekspresjon av isoprenylprotein-transferaser
TR200100637T2 (tr) Yeni doğal ürün türevleri
NO20030802L (no) Aminoalkoksybenzoyl-benzofuran- eller benzotiofenderivater, fremgangsmåte for deres fremstilling og preparater inneholdende de samme
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
ES2110057T3 (es) Composicion medicinal que contiene tcf-ii.
NO995692D0 (no) Nye BPC-peptidsalter med organbeskyttende aktivitet, metoden for deres fremstilling og deres anvendelse
NO20006547L (no) Salter av paroxetine
BR0015121A (pt) Composição farmacêutica utilizável para o tratamento de inflamação em humanos, e, método de tratamento de inflamação
DE60010934D1 (de) Medikamente geeignet zur Behandlung von proliferativen Erkrankungen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application